Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20071775 | 0.84 | MAPK1 (0.32) | MAPK1KMT2A | |
| SCHEMBL20062963 | 0.81 | MAPT (0.31) | MAPTSMN1; SMN2ALDH1A1HPGDALOX15 | |
| SCHEMBL20071774 | 0.79 | AR (0.38) | ALDH1A1HPGDMAPK1 | |
| SCHEMBL20681894 | 0.69 | ALDH1A1 (0.33) | MAPTSMN1; SMN2ALDH1A1HPGDALOX15 | |
| SCHEMBL18911705 | 0.68 | MAPT (0.33) | MAPTSMN1; SMN2ALDH1A1HPGDALOX15 | |
| SCHEMBL20072095 | 0.68 | HCRTR1 (0.42) | MAPTSMN1; SMN2ALDH1A1HPGDALOX15 | |
| SCHEMBL20681889 | 0.68 | KIF11 (0.43) | MAPTSMN1; SMN2ALDH1A1HPGDALOX15 | |
| SCHEMBL20071768 | 0.68 | SCN10A (0.33) | MAPTSMN1; SMN2ALDH1A1HPGDALOX15 | |
| SCHEMBL20071952 | 0.68 | RXRB (0.32) | — | |
| SCHEMBL20071947 | 0.67 | SCN10A (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10541260-B2 | Organic photoelectric conversion element, optical area sensor, imaging device, and imaging apparatus | CANON KABUSHIKI KAISHA (JP) | 2020-01-21 | — | — | US | disclosed |
| US-10193084-B2 | 2,2′-bibenzo[D]imidazolidene compound having heteromonocyclic groups at the 1-, 1′-, 3- and 3′- positions, and organic light-emitting element and display device containing the same | CANON KABUSHIKI KAISHA (JP) | 2019-01-29 | — | — | US | disclosed |
| US-20180108691-A1 | ORGANIC PHOTOELECTRIC CONVERSION ELEMENT, OPTICAL AREA SENSOR, IMAGING DEVICE, AND IMAGING APPARATUS | CANON KABUSHIKI KAISHA (JP) | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10193084-B2 | 2,2′-bibenzo[D]imidazolidene compound having heteromonocyclic groups at the 1-, 1′-, 3- and 3′- positions, and organic light-emitting element and display device containing the same | BRD1, DRD1, NR2E3 | MAPT 3694/4885SMN1; SMN2 2289/4885ALDH1A1 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.